This notion is supported by a study showing that blockade of FcγRIIIA by monoclonal antibodies recapitulates IVIG activity and efficiently ameliorates inflammatory responses in refractory ITP patients, although FcγRIIIA crosslinking results in adverse side effects22. This evidence concerns the gene FCGR3A and autoimmune thrombocytopenic purpura.